73
Participants
Start Date
September 2, 2021
Primary Completion Date
April 16, 2025
Study Completion Date
April 16, 2025
Progesterone
Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Ibutilide
Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval
Testosterone
Subjects will apply transdermal testosterone gel once daily every morning for 3 days
Placebo
Lactose capsules
Indiana Clinical Research Center, Indianapolis
Indiana University, Indianapolis
Purdue University, Indianapolis
Purdue University
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Harvard University
OTHER
Cedars-Sinai Medical Center
OTHER
Indiana University
OTHER